Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

NCT05660967 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

BIOLOGICAL: Epcoritamab
DRUG: Lenalidomide

Sponsor

Genmab

Collaborators

[object Object]